Related Experiment Videos
Synthesis and separation of optically active compounds. Part I
Y Gao1, E Boschetti, L Guerrier
1Sepracor Inc, Marlborough, MA 01752.
Annales Pharmaceutiques Francaises
|January 1, 1994
Summary
Regulatory guidelines now mandate pure enantiomer drugs due to stereoselective biological activity. Advances in asymmetric synthesis and chiral separation enable cost-effective, large-scale production of single enantiomer pharmaceuticals.
Area of Science:
- Chiral Chemistry
- Pharmaceutical Synthesis
- Drug Development
Background:
- Biological processes exhibit high stereoselectivity, with pharmacological activity often linked to a single enantiomer.
- Regulatory bodies now require chiral drugs to be marketed as pure, safe, and effective single enantiomers.
Purpose of the Study:
- To review the industrial applications and economic viability of asymmetric synthesis and chiral separation techniques.
- To highlight the importance of producing optically pure drugs to meet regulatory standards and ensure therapeutic efficacy.
Main Methods:
- Asymmetric synthesis using chiral auxiliaries or catalysts (enzymes, metal complexes) to create chiral centers from prochiral molecules.
- Racemate resolution techniques including crystallization, enzymatic resolution, and liquid chromatography for preparative scale drug development.
Main Results:
- Asymmetric synthesis provides an economical advantage by producing exclusively the targeted enantiomer.
- Resolution methods, despite producing both enantiomers, are valuable for preclinical studies and widely used industrially due to racemization/recycling feasibility.
Conclusions:
- The production of optically pure drugs is becoming a necessity in the pharmaceutical industry.
- Current advancements in chiral synthesis and separation technologies facilitate the industrial-scale manufacturing of enantiomerically pure active pharmaceutical ingredients.